Literature DB >> 3225401

Serum levels of the oncofetal antigens CA-125, CA 19-9 and CA 15-3 in patients with endometriosis.

D Panidis1, G Vlassis, J Matalliotakis, S Skiadopoulos, A Kalogeropoulos.   

Abstract

The levels of the oncofetal antigens CA-125, CA 19-9 and CA 15-3 were measured in serum samples taken from 8 women, aged 21 to 37 yr, before treatment, during the last fifteen days of a 6-month administration of danazol and finally three months after treatment withdrawal. The purpose of the study was to investigate: i) whether endometriosis belongs to the pathologic conditions which induce a concomitant increase in the values of CA-125, CA 19-9 and CA 15-3, and ii) the effect of danazol on the levels of these antigens. Our results indicate that before danazol treatment, three women showed pathologic levels of all three antigens, one of CA 19-9 and CA 15-3, one of CA 19-9 alone, and two of CA 15-3 alone. Administration of the drug significantly reduced the levels of CA-125 (p less than 0.001) and CA 19-9 (p less than 0.05) and to a lesser degree the levels of CA 15-3. Three months after danazol treatment discontinuation, the levels of these three antigens remained significantly lower (p less than 0.05) than the respective pretreatment values. Our findings substantiate the view that endometriosis must be classified with the pathologic conditions which induce a rise in the levels of all three antigens, and that ovarian function mainly influences the levels of CA-125 and CA 19-9.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3225401     DOI: 10.1007/BF03350229

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  17 in total

1.  CA-125 in patients with endometriosis.

Authors:  R L Barbieri
Journal:  Fertil Steril       Date:  1986-06       Impact factor: 7.329

2.  CA 15.3: early results of a new breast cancer marker.

Authors:  R Colomer; L A Sole; M Navarro; G Encabo; A Ruibal; L Salvador
Journal:  Anticancer Res       Date:  1986 Jul-Aug       Impact factor: 2.480

3.  Cancer drug targeting.

Authors:  K D Bagshawe
Journal:  Clin Radiol       Date:  1985-11       Impact factor: 2.350

4.  Endometriosis and infertility.

Authors:  W P Dmowski; E Radwanska
Journal:  Acta Obstet Gynecol Scand Suppl       Date:  1984

5.  Evaluation of serum CA125 values in healthy individuals and pregnant women.

Authors:  Y Haga; K Sakamoto; H Egami; R Yoshimura; M Akagi
Journal:  Am J Med Sci       Date:  1986-07       Impact factor: 2.378

6.  Radioimmunometric assay for a monoclonal antibody-defined tumor marker, CA 19-9.

Authors:  B C Del Villano; S Brennan; P Brock; C Bucher; V Liu; M McClure; B Rake; S Space; B Westrick; H Schoemaker; V R Zurawski
Journal:  Clin Chem       Date:  1983-03       Impact factor: 8.327

7.  The second-look laparoscopy for evaluation of the result of medical treatment of endometriosis should not be performed during ovarian suppression.

Authors:  J L Evers
Journal:  Fertil Steril       Date:  1987-03       Impact factor: 7.329

8.  A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer.

Authors:  R C Bast; T L Klug; E St John; E Jenison; J M Niloff; H Lazarus; R S Berkowitz; T Leavitt; C T Griffiths; L Parker; V R Zurawski; R C Knapp
Journal:  N Engl J Med       Date:  1983-10-13       Impact factor: 91.245

9.  Elevated serum concentrations of CA-125 in patients with advanced endometriosis.

Authors:  R L Barbieri; J M Niloff; R C Bast; E Scaetzl; R W Kistner; R C Knapp
Journal:  Fertil Steril       Date:  1986-05       Impact factor: 7.329

10.  Monitoring human ovarian carcinoma with a combination of CA 125, CA 19-9, and carcinoembryonic antigen.

Authors:  R C Bast; T L Klug; E Schaetzl; P Lavin; J M Niloff; T F Greber; V R Zurawski; R C Knapp
Journal:  Am J Obstet Gynecol       Date:  1984-07-01       Impact factor: 8.661

View more
  2 in total

Review 1.  Peripheral biomarkers of endometriosis: a systematic review.

Authors:  K E May; S A Conduit-Hulbert; J Villar; S Kirtley; S H Kennedy; C M Becker
Journal:  Hum Reprod Update       Date:  2010-05-12       Impact factor: 15.610

Review 2.  Oncofetal reprogramming in tumour development and progression.

Authors:  Ankur Sharma; Camille Blériot; Jennifer Currenti; Florent Ginhoux
Journal:  Nat Rev Cancer       Date:  2022-08-23       Impact factor: 69.800

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.